Reduced IL-33 plasma levels in aplastic anemia.

IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model. PLoS Med (2017) 0.76

Current concepts in the pathophysiology and treatment of aplastic anemia. Blood (2006) 5.20

Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol (2010) 4.92

IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev (2008) 4.68

IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A (2010) 3.07

IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 2.99

IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol (2008) 2.83

Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A (1985) 2.33

Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29

Aplastic anaemia. Lancet (2005) 2.10

The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest (2003) 2.09

Role of IL-33 in inflammation and disease. J Inflamm (Lond) (2011) 2.06

Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood (2010) 1.91

Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum (2013) 1.84

Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood (2002) 1.72

Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol (1995) 1.33

gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med (1994) 1.26

IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol (2012) 1.25

Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure (2009) 1.24

Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) (2009) 1.11

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol (2015) 1.08

Targeting the IL17 pathway for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant (2014) 0.90

Interleukin (IL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia. Br J Haematol (2008) 0.90

The IL-17 cytokine family members are inhibitors of human hematopoietic progenitor proliferation. Blood (2006) 0.87

Acquired aplastic anemia. Clin Lab Sci (2004) 0.86

A role for soluble ST2 in vascular remodeling associated with obesity in rats. PLoS One (2013) 0.83

Immune mechanism of aplastic anemia. Int J Hematol (1997) 0.82

Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3⁺ regulatory T cells in skin-transplanted mice. Immunology (2015) 0.81

[Th17 lymphocytes in bacterial infections]. Postepy Hig Med Dosw (Online) (2015) 0.77

Basal level of Th17 immune response is not enhanced in aplastic amemia. Cytokine (2015) 0.77

[Association between serum interleukin-17 level and abnormal cellular immunological status in patients with severe aplastic anemia]. Zhonghua Yi Xue Za Zhi (2014) 0.76